@article{10902/29828,
year = {2023},
url = {https://hdl.handle.net/10902/29828},
abstract = {Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disorders ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). Hepatic steatosis may result from the dysfunction of multiple pathways and thus multiple molecular triggers involved in the disease have been described. The development of NASH entails the activation of inflammatory and fibrotic processes. Furthermore, NAFLD is also strongly associated with several extra-hepatic comorbidities, i.e., metabolic syndrome, type 2 diabetes mellitus, obesity, hypertension, cardiovascular disease and chronic kidney disease. Due to the heterogeneity of NAFLD presentations and the multifactorial etiology of the disease, clinical trials for NAFLD treatment are testing a wide range of interventions and drugs, with little success. Here, we propose a narrative review of the different
phenotypic characteristics of NAFLD patients, whose disease may be triggered by different agents
and driven along different pathophysiological pathways. Thus, correct phenotyping of NAFLD
patients and personalized treatment is an innovative therapeutic approach that may lead to better
therapeutic outcomes.},
publisher = {MDPI},
publisher = {International Journal of Molecular Sciences, 2023, 24(13), 10718},
title = {Innovative therapeutic approaches in non-alcoholic fatty liver disease: when knowing your patient is key},
author = {Alonso Peña, Marta and Barrio Azaceta, María del and Peleteiro Vigil, Ana and Jiménez González, Carolina and Santos Laso, Álvaro and Arias Loste, María Teresa and Iruzubieta Coz, Paula and Crespo García, Javier},
}